Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to JNJ Innovative ...

Learn more about whether Alvotech or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades ...

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for psoriasis ...

Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for ...